ArticleInternational journal of cancer2026
The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
We previously showed that ZDHHC11 promotes cell growth in Burkitt lymphoma (BL). To explore the underlying mechanism, we performed a genome-wide gene expression analysis upon ZDHHC11 knockdown. We identified MEF2B, a transcription factor critical for germinal center formation, as a downstream target and validated repression of MEF2B at the RNA and protein level upon ZDHHC11 knockdown in BL cell lines. The relevance of MEF2B was shown upon its knockdown, which strongly inhibited growth of BL cells. Since MEF2B is a known regulator of BCL6 in normal GC B-cells, diffuse large B-cell lymphoma, and follicular lymphoma, we subsequently focused on the effect of MEF2B knockdown on BCL6. We observed a strong decrease in BCL6 at the RNA and protein level in BL and showed a strong correlation between MEF2B and BCL6 transcript levels in a panel of B-cell lymphoma cell lines, primary BL samples, and normal B-cell subsets. Knockdown of BCL6 also strongly inhibited growth of BL cell lines, whereas BCL6 overexpression partially rescued the growth-inhibitory effect of MEF2B knockdown. Together, our data indicate that ZDHHC11 promotes BL cell growth at least in part by stimulating expression of MEF2B, which promoted BL cell survival through both BCL6-dependent and independent pathways. Our work highlighted the importance of the MEF2B-BCL6 axis, which strongly supports BL growth and identified ZDHHC11 as a novel regulator of this axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.